title: Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial.
abstract: BACKGROUND
  Early improvements in disease-free survival have been noted when an aromatase inhibitor is given either instead of or sequentially after tamoxifen in postmenopausal women with oestrogen-receptor-positive early breast cancer. However, little information exists on the long-term effects of aromatase inhibitors after treatment, and whether these early improvements lead to real gains in survival.
  
  
  METHODS
  4724 postmenopausal patients with unilateral invasive, oestrogen-receptor-positive or oestrogen-receptor-unknown breast cancer who were disease-free on 2-3 years of tamoxifen, were randomly assigned to switch to exemestane (n=2352) or to continue tamoxifen (n=2372) for the remainder of a 5-year endocrine treatment period. The primary endpoint was disease-free survival; overall survival was a secondary endpoint. Efficacy analyses were intention-to-treat. This study is registered as an International Standard Randomised Controlled Trial, number ISRCTN11883920.
  
  
  RESULTS
  After a median follow-up of 55.7 months (range 0-89.7), 809 events contributing to the analysis of disease-free survival had been reported (354 exemestane, 455 tamoxifen); unadjusted hazard ratio 0.76 (95% CI 0.66-0.88, p=0.0001) in favour of exemestane, absolute benefit 3.3% (95% CI 1.6-4.9) by end of treatment (ie, 2.5 years after randomisation). 222 deaths occurred in the exemestane group compared with 261 deaths in the tamoxifen group; unadjusted hazard ratio 0.85 (95% CI 0.71-1.02, p=0.08), 0.83 (0.69-1.00, p=0.05) when 122 patients with oestrogen-receptor-negative disease were excluded.
  
  
  CONCLUSIONS
  Our results suggest that early improvements in disease-free survival noted in patients who switch to exemestane after 2-3 years on tamoxifen persist after treatment, and translate into a modest improvement in overall survival.
authors.affiliation: Cancer Research UK Department of Cancer Medicine, Division of Surgery, Oncology, Reproductive Biology and Anaesthetics, Imperial College London, Faculty of Medicine, Hammersmith Hospitals Trust, London W12 0NN, UK.
authors.forename: R C
authors.initials: RC
authors.lastname: Coombes
authors.forename: L S
authors.initials: LS
authors.lastname: Kilburn
authors.forename: C F
authors.initials: CF
authors.lastname: Snowdon
authors.forename: R
authors.initials: R
authors.lastname: Paridaens
authors.forename: R E
authors.initials: RE
authors.lastname: Coleman
authors.forename: S E
authors.initials: SE
authors.lastname: Jones
authors.forename: J
authors.initials: J
authors.lastname: Jassem
authors.forename: C J H
authors.initials: CJ
authors.lastname: Van de Velde
authors.forename: T
authors.initials: T
authors.lastname: Delozier
authors.forename: I
authors.initials: I
authors.lastname: Alvarez
authors.forename: L
authors.initials: L
authors.lastname: Del Mastro
authors.forename: O
authors.initials: O
authors.lastname: Ortmann
authors.forename: K
authors.initials: K
authors.lastname: Diedrich
authors.forename: A S
authors.initials: AS
authors.lastname: Coates
authors.forename: E
authors.initials: E
authors.lastname: Bajetta
authors.forename: S B
authors.initials: SB
authors.lastname: Holmberg
authors.forename: D
authors.initials: D
authors.lastname: Dodwell
authors.forename: E
authors.initials: E
authors.lastname: Mickiewicz
authors.forename: J
authors.initials: J
authors.lastname: Andersen
authors.forename: P E
authors.initials: PE
authors.lastname: Lønning
authors.forename: G
authors.initials: G
authors.lastname: Cocconi
authors.forename: J
authors.initials: J
authors.lastname: Forbes
authors.forename: M
authors.initials: M
authors.lastname: Castiglione
authors.forename: N
authors.initials: N
authors.lastname: Stuart
authors.forename: A
authors.initials: A
authors.lastname: Stewart
authors.forename: L J
authors.initials: LJ
authors.lastname: Fallowfield
authors.forename: G
authors.initials: G
authors.lastname: Bertelli
authors.forename: E
authors.initials: E
authors.lastname: Hall
authors.forename: R G
authors.initials: RG
authors.lastname: Bogle
authors.forename: M
authors.initials: M
authors.lastname: Carpentieri
authors.forename: E
authors.initials: E
authors.lastname: Colajori
authors.forename: M
authors.initials: M
authors.lastname: Subar
authors.forename: E
authors.initials: E
authors.lastname: Ireland
authors.forename: J M
authors.initials: JM
authors.lastname: Bliss
mesh_terms: D000368:Aged; D000730:Androstadienes / Q000009:adverse effects / Q000627:therapeutic use*; D047072:Aromatase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D018572:Disease-Free Survival; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D017698:Postmenopause; D020845:Selective Estrogen Receptor Modulators / Q000009:adverse effects / Q000627:therapeutic use*; D016019:Survival Analysis; D013629:Tamoxifen / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000730:Androstadienes; D047072:Aromatase Inhibitors; D020845:Selective Estrogen Receptor Modulators; D013629:Tamoxifen; C056516:exemestane